

## FROM THE JOURNALS



## The following Editors' Choice articles appear in the July and August 2018 issues of *Value in Health*.

For more information, visit: [www.ispor.org/valuehealth\\_index.asp](http://www.ispor.org/valuehealth_index.asp).

### July 2018

#### BRIEF REPORT

##### Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost per Disability Adjusted Life-Years Studies

Ashley Leech, David Kim, Joshua Cohen, Peter Neumann

*Previous literature has addressed pros and cons of using generic economic thresholds to determine the cost-effectiveness of an intervention, while other studies have pointed to alternative approaches to valuing care. In this brief report, the authors examine the evolution of thresholds in the cost-effectiveness literature for low and middle-income countries and analyze whether these studies appropriately justified the use of these values.*

#### ECONOMIC EVALUATION

##### Cost-Effectiveness Analysis in Telehealth: A Comparison between Home Telemonitoring, Nurse Telephone Support, and Usual Care in Chronic Heart Failure Management

Andrija S. Grustam, Johan L. Severens, Daniele De Massari, Nasuh Buyukkaramikli, Ron Koymans, Hubertus J.M. Vrijhoef

*The aim of this study is to provide insights into the cost-effectiveness of a telehealth (ie, telemonitoring) system in The Netherlands from a third-party payer's perspective. The authors assessed whether home telemonitoring or nurse telephone support were cost-effective strategies in the management of congestive heart failure, compared with usual care. They also explored whether there is a subgroup of congestive heart failure patients that can benefit the most from telemonitoring.*

#### PREFERENCE-BASED ASSESSMENT

##### Uncertainty and the Under-Valuation of Services for Severe Health States in Cost Utility Analyses

Jeff Ralph Richardson, Angelo Iezzi, Aimee Maxwell

*A number of psychological factors that affect measurement under uncertainty do not affect utility as currently measured. The aim of this study was to test the 'uncertainty aversion hypothesis' by generating a scoring algorithm weighted on the preferences of consumers for assessing the quality of care in nursing homes.*

### August 2018

#### COMPARATIVE-EFFECTIVENESS RESEARCH/HTA

##### Surveying the Cost-Effectiveness of the Twenty Procedures With the Largest Public Health Services Waiting Lists in Ireland: Implications for Ireland's Cost-Effectiveness Threshold

Tse Chiang Chen, Dane Wanniarachige, Síofra Murphy, Katie Lockhart, James O'Mahony

*The authors survey the cost-effectiveness of procedures with the largest waiting lists in the Irish public health system in order to inform a reconsideration of Ireland's current cost-effectiveness threshold of €45,000/quality-adjusted life-year.*

#### ECONOMIC EVALUATION

##### Productivity Benefits of Medical Care: Evidence from US-Based Randomized Clinical Trials

Alice Chen, Dana Goldman

*This paper examines the relationship between new drug treatments and gains in labor productivity across conditions in the United States and evaluates which randomized clinical trials collect productivity data.*

#### HEALTH POLICY ANALYSIS

##### Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC: Does the Presence of an Explicit Threshold Affect the ICER Proposed?

Shuhong Wang, Debra Gum, Tracy Merlin

*The authors compared the initial incremental cost-effectiveness ratios (ICERs) presented by manufacturers in matched submissions to each decision-making body, with the aim of exploring the impact of an explicit threshold on these ICERs.*

#### METHODOLOGY

##### Sharing and the Provision of 'Cost Ineffective' Life-Extending Services to Less Severely Ill Patients

Jeff Richardson, Angelo Iezzi, Aimee Maxwell

*This paper examines whether this preference for sharing persists for less severe conditions when both cost-effectiveness and illness severity would indicate that resources should be allocated to other services.*

#### PATIENT-REPORTED OUTCOMES

##### Patient-Reported Outcome Measures in the FDA Pilot Compendium: Meeting Today's Standards for Patient Engagement in Development?

Elisabeth Oehrlein, Eleanor Peretto, Thelma Love, Yujin Chung, Parima Ghafoori

*In 2016, the US FDA released a Pilot Clinical Outcome Assessment Compendium intended to foster patient-focused drug development. In this study, the authors find that most of the patient-reported outcomes measures in the sample examined violate a fundamental premise to engage patients in the development process.*

#### PREFERENCE-BASED ASSESSMENTS

##### Advocating a Paradigm Shift in Health-State Valuations: The Estimation of Time-Preference Corrected QALY Tariffs

Marcel Jonker, Bas Donkers, Esther de Bekker-Grob, Elly Stolk

*This paper introduces a general method of accommodating for non-linear time preferences in discrete choice experiment duration studies and to evaluate its impact on estimated QALY tariffs.*



**The following Editors' Choice articles appeared in the May 2018 issue of *Value in Health Regional Issues*.**

Appropriate use of health economics and outcomes research (HEOR) can provide detailed insight and profound information for healthcare decision makers. Healthcare systems in Asia Pacific countries are facing many challenging tasks and implementing reform policies. The research published in *Value in Health Regional Issues* can help educate readers and healthcare stakeholders about how to use HEOR for emerging themes in the Asia Pacific region. For more information about the journal and to read the current issue, visit: <https://www.ispor.org/publications/VIHRI/index.asp>

**THEMED SECTION: DRUG POLICIES IN ASIA**

**Recent Pricing Negotiations on Innovative Medicines in China: Experiences, Trends, and Implications**

Hong Li, Gordon Liu, Jing Wu, Jiu-Hong Wu, Chao-Hui Dong, Shan-Lian Hu

**New Drug Reimbursement and Pricing Policy in Taiwan**

Gau-Tzu Chen, Shu-Chen Chang, Chee-Jen Chang

**Health Technology Assessment and Its Use in Drug Policies in China**

Xuemei Zhen, Xueshan Sun, Hengjin Dong

**ECONOMIC EVALUATION**

**Modeling Possible Inclusion of Pneumococcal Conjugate Vaccine into the National Immunization Program for Infants in India**

Canna Ghia, Matt Wasserman, Mark Fletcher; Ray Farkouh, Gautam Rambhad

*Using a well-established pneumococcal disease impact model parameterized with local data to the extent possible, the authors calculated the potential impact of introducing an infant pneumococcal conjugate vaccine program in India.*

**PATIENT-REPORTED OUTCOMES**

**Health-Related Quality of Life of Patients With Human Papilloma Virus-Related Cancers in Indonesia**

Antoinette D. van Asselt, Arrum Dusafitri, Didik Setiawan, Githa F. Galistiani, Maarten J. Postma

*In comparison to existing reference utility index for healthy population, health-related quality of life of patients with human papilloma virus-related cancers was found to be reduced to a certain extent in this study in Indonesia.*

< ADVERTISEMENT >

**Grow Your Business with Our Access & Value Solutions**  
 Designed to help you evaluate therapeutic performance in the real world

**Key features**

- Access cloud-based, expertly curated disease models, powered by our proprietary IBM® MarketScan® Research Databases, Explorys® EMR data, and linked Claims-EMR Data Set
- Visually explore and compare therapy-specific clinical and financial outcomes
- Estimate the financial impact of adding new therapies to formulary with value calculators
- Monitor the performance of enrolled populations under value-based contracts

**Benefits**

- No advanced statistical or clinical knowledge necessary for running exploratory HEOR studies
- Gain instant access to the most recent real-world data and outcomes across any disease
- Streamline the process of value-based contracting
- Build trust and transparency in your value dossiers

Take advantage of our 2018 Promotions:  
 Up to **30% discount** on disease models

[Click here](#) to schedule a meeting with your account rep



© Copyright IBM Corporation 2018. IBM, the IBM logo and ibm.com are trademarks of IBM Corporation in the United States, other countries or both. Other product and service names might be trademarks of IBM or other companies. LS 19258 0718